Ovarian cancer is usually detected at a late stage, and there is no method for diagnosing its latent form. After treatment, only 25% of patients survive, but the new discovery is likely to increase the chances of patients.

Kundle Oduntsi, a professor of gynecology and oncology at the Roswell Park Cancer Institute in New York, is testing a vaccine that destroys a specific protein found in male testicles, but also found in ovarian cancer cells.

"We are able to induce healthy immune responses," said the author of the study.

Twenty-two women participated in the trial, and 70% of them had a positive reaction to the vaccine. In another study, it turned out that the vaccine delayed the recurrence of cancer for two years.

The goal is to prevent the recurrence of the disease and prolong the survival rate.

Vaccination is carried out once for seven months. In addition to redness in the area of ??injection, other side effects were not observed health. Sumy. Ua.

Keywords:.